Company Info

Industry Biotechnology
Sector Health Technology
Employees n/a
CEO Mr. Sujal M. Patel
Address 425 Pontius Avenue North Suite 202, Seattle, WA 98109
Phone n/a

Nautilus Biotechnology, Inc. develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.


Company Name 3 Month
1 Year
Nautilus Biotechnology, Inc. -40.87% -49.81%
Ventyx Biosciences, Inc. n/a n/a
Rani Therapeutics Holdings, Inc. n/a n/a
Aclaris Therapeutics, Inc. 2.09% 276.47%
Avidity Biosciences, Inc. -8.98% -22.42%

Statement Summary

as of 4:00 ET PM 10/21/2021
Total Assets (MRQ) 393.3 M
Total Liabilities (MRQ) 3.2 M
Shareholders’ Equity (MRQ) 390.0 M
Total Revenue (Annual) n/a
Net Income (Annual) -10.7 M

Earnings And Estimates

as of 4:00 ET PM 10/21/2021

Current Qtr EPS Estimate -0.10
Current FY EPS Estimate -0.61
Long Term EPS Growth Estimate n/a
Next Expected Earnings Date 11/2/2021

NAUT vs S&P 500

as of 10/21/2021
Relative To
S&P 500
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 10/21/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.07 -0.19 +171.43%

Financial Strength

as of 4:00 ET PM 10/21/2021
Pre-Tax Margin 0.00
Net Margin 0.00
Operating Margin 0.00
Return On Equity -6.66
Return On Assets -6.60
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) n/a


as of 4:00 PM ET 10/21/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 1.73
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) 3.14
Quick Ratio (MRQ) 115.95
Current Ratio (MRQ) 115.95
Total Debt/Equity (MRQ) 0.00

Short Interest

as of 11:24 AM ET 10/22/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
Cash from
0,0.00 0,0.00
Cash from
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00




Balance Sheet

Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00


EBT Excluding Unusual Items


Income Statement

Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Dividends Paid Per Share 0,0.00




Cash Flow Statement

Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 10/21/2021
Current Qtr
Next Qtr
Consensus Estimate $-0.10 $-0.11
# of Estimates 2 2
High Estimate $-0.09 $-0.10
Low Estimate $-0.11 $-0.12
Year Ago EPS $-0.01 $-0.02
Year Over Year Growth Estimate 1,104.82% 497.83%
Current Yr
Next Yr
Consensus Estimate $-0.61 $-0.69
# of Estimates 2 2
High Estimate $-0.59 $-0.68
Low Estimate $-0.62 $-0.69
Year Ago EPS $-0.46 $-0.61
Year Over Year Growth Estimate 31.52% 13.22%
Current Qtr
Next Qtr
Current Year
Next Year
Consensus Estimate $-0.10 $-0.11 $-0.61 $-0.69
# of Estimates 2 2 2 2
High Estimate $-0.09 $-0.10 $-0.59 $-0.68
Low Estimate $-0.11 $-0.12 $-0.62 $-0.69
Year Ago EPS $-0.01 $-0.02 $-0.46 $-0.61
Year Over Year Growth Estimate 1,104.82% 497.83% 31.52% 13.22%

Insider Information Summary

as of 09/30/2021
% Insiders - 72.52%
% Remaining Total Shares - 27.48%
Current 1 Month
Net Insider Transaction 59.47 K 4.04 M
Shares Bought 59.47 K 4.54 M
Shares Sold 0.00 499.00 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings


Recent Articles from TheStreet

Seagate Technology

Seagate Shares Rise on Stronger-Than-Expected Earnings

Seagate Technology shares rose after the disk-drive maker reported stronger-than-expected earnings and buoyant guidance.

Wall Street Lead

Dow, S&P 500 Slide As Fed Chair Powell Cautions on Inflation, Says Taper Plans 'On Track'

Wall Street retreated from fresh record highs Friday as Fed Chair Jerome Powell said the central bank is "on track" to being tapering the pace of its monthly bond purchases.

23andMe Lead

23andMe Stock Drops on Plan to Buy Health Platform Lemonaid

23andMe shares drop after the consumer genetics company definitively agrees to pay $400 million for health platform Lemonaid.

Pfizer vaccine Lead

Pfizer-BioNTech Covid Vaccine Shows Efficacy Above 90% for Kids

Pfizer and BioNTech's children's Covid-19 vaccine should be the topic of discussion when the FDA's vaccine advisory committee meets Tuesday.

Tesla Lead

Tesla Stock Hits Record High, With $1 Trillion Valuation In Sight, After Q3 Earnings Surge

Tesla is now within clear sight of a $1 trillion valuation after shares in the group hit a fresh all-time high following record third quarter earnings earlier this week.

Zoom Five9 Lead

Zoom Video Stock Rises After JPMorgan Upgrade

JPMorgan analyst upgraded Zoom Video and said the videoconferencing app could be a winner in enterprise or B2B communication.

trump-questions (1)

Digital World, SPAC Tied to Trump, More Than Doubles

Shares of Digital World, the SPAC through which Trump Media & Technology Group is going public, as much as more than doubled on Friday.

Beyond Meat Sausage Breakfast Yuck Lead

Beyond Meat Drops as It Lowers Q3 Revenue Expectations

Beyond Meat slashed it third quarter revenue forecast Friday, citing weakening demand, supply chain disruptions and the lingering impact of COVID-19.

Why Whirlpool Shares Have Room to Climb

Whirlpool Stock Drops as Ongoing Supply Chain Issues Impact Sales

Whirlpool shares fall after reporting mixed results for the quarter, topping bottom-line estimates while missing on revenue amid ongoing supply chain woes.

Snap Lead

Premarket Movers Friday - Snap, Digital World Trump SPAC, Intel

Stocks moving in premarket trading include Snap, Digital World (the Trump SPAC), Intel, Mattel and Zoom.